GLUE

Monte Rosa Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · monterosatx.com

$19.57

Mkt Cap $1.3B

52w Low $3.51 72.1% of range 52w High $25.77

50d MA $17.69 200d MA $13.61

P/E (TTM) -40.9x

EV/EBITDA -26.4x

P/B 6.7x

Debt/Equity 0.2x

ROE 8.5%

P/FCF -47.4x

RSI (14) —

ATR (14) —

Beta 1.64

50d MA $17.69

200d MA $13.61

Avg Volume 1.1M

About

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The comp…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 17, 2026	AMC	-0.35	-0.54	-53.6%	16.03	-1.1%	-1.7%	+0.2%	-2.5%	-6.2%	-8.2%	+16.7%	—
Nov 6, 2025	AMC	-0.37	-0.33	+9.9%	13.01	-2.2%	-5.4%	+8.1%	+10.1%	+8.8%	+10.1%	+37.2%	—
Aug 7, 2025	AMC	-0.38	-0.15	+60.2%	4.23	-0.7%	+3.5%	-0.9%	+5.2%	+5.0%	+2.8%	+13.5%	—
May 8, 2025	AMC	-0.00	0.57	+9999.0%	4.22	+0.5%	-3.1%	+1.2%	-4.3%	-12.3%	-8.3%	+16.6%	—
Mar 20, 2025	AMC	0.02	0.23	+1379.4%	7.06	-0.1%	-17.8%	-17.4%	-19.7%	-22.2%	-25.5%	-36.8%	—
Nov 7, 2024	AMC	-0.49	-0.29	+40.8%	9.53	+3.0%	-2.8%	+5.0%	-4.2%	-9.4%	-11.0%	+7.0%	—
Aug 8, 2024	AMC	-0.54	-0.43	+20.4%	3.98	+0.8%	-1.0%	+0.0%	+21.1%	+13.1%	+23.1%	+49.0%	—
May 9, 2024	AMC	-0.57	-0.53	+7.0%	5.18	+0.8%	-6.4%	-4.4%	-3.5%	+1.0%	+0.8%	-22.4%	—
Mar 14, 2024	AMC	-0.33	-0.58	-75.8%	6.09	+0.0%	+5.3%	+10.0%	+13.6%	+22.3%	+24.6%	+7.9%	—
Nov 9, 2023	AMC	-0.72	-0.70	+2.8%	3.30	+0.0%	-2.7%	-7.4%	+3.3%	+11.5%	-1.8%	+27.3%	—
Aug 10, 2023	AMC	-0.70	-0.71	-1.4%	6.68	+1.0%	+0.1%	-2.2%	-1.5%	-3.1%	-4.5%	-9.6%	—
May 11, 2023	AMC	-0.68	-0.65	+4.4%	5.85	-2.2%	-2.9%	+0.0%	-4.4%	-3.4%	-5.3%	+17.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 18	Wells Fargo	Maintains	Overweight → Overweight	—	$16.03	$15.86	-1.1%	-1.7%	+0.2%	-2.5%	-6.2%	-8.2%
Mar 18	Guggenheim	Maintains	Buy → Buy	—	$16.03	$15.86	-1.1%	-1.7%	+0.2%	-2.5%	-6.2%	-8.2%
Jan 14	Piper Sandler	Maintains	Overweight → Overweight	—	$23.99	$23.99	+0.0%	+0.3%	+0.4%	-1.2%	+1.9%	+1.0%
Jan 8	Wells Fargo	Maintains	Overweight → Overweight	—	$23.28	$23.36	+0.3%	+8.7%	+4.3%	+1.9%	+3.0%	+3.4%
Jan 8	Guggenheim	Maintains	Buy → Buy	—	$23.28	$23.36	+0.3%	+8.7%	+4.3%	+1.9%	+3.0%	+3.4%
Dec 16	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$16.45	$17.19	+4.5%	+13.4%	+1.8%	-3.8%	-5.5%	-1.6%
Nov 7	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$13.01	$12.73	-2.2%	-5.4%	+8.1%	+10.1%	+8.8%	+10.1%
Mar 21	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$7.06	$7.05	-0.1%	-17.8%	-17.4%	-19.7%	-22.2%	-25.5%
Mar 21	Wedbush	Maintains	Outperform → Outperform	—	$7.06	$7.05	-0.1%	-17.8%	-17.4%	-19.7%	-22.2%	-25.5%
Dec 19	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$7.03	$6.81	-3.1%	-7.4%	-1.4%	+1.6%	+0.3%	+2.7%
Sep 12	Wedbush	Maintains	Outperform → Outperform	—	$6.22	$6.22	+0.0%	-4.2%	-2.3%	-9.6%	-4.8%	-4.3%
Aug 12	Wells Fargo	Maintains	Overweight → Overweight	—	$3.94	$3.98	+1.0%	+1.0%	+22.3%	+14.2%	+24.4%	+18.8%
Jun 28	Piper Sandler	Maintains	Overweight → Overweight	—	$3.38	$3.32	-1.8%	+10.7%	+16.6%	+6.2%	+15.1%	+7.7%
May 22	Wedbush	Maintains	Outperform → Outperform	—	$4.30	$4.47	+4.0%	-2.1%	-7.2%	-3.3%	-2.8%	-7.0%
Oct 19	JP Morgan	Maintains	Overweight → Overweight	—	$3.43	$3.36	-2.0%	-8.9%	-20.1%	-22.7%	-24.8%	-27.1%
Aug 11	Credit Suisse	Maintains	Neutral → Neutral	—	$6.68	$6.75	+1.0%	+0.1%	-2.2%	-1.5%	-3.1%	-4.5%
May 12	Credit Suisse	Maintains	Neutral → Neutral	—	$5.85	$5.72	-2.2%	-2.9%	+0.0%	-4.4%	-3.4%	-5.3%
Mar 17	Credit Suisse	Maintains	Neutral → Neutral	—	$7.01	$6.87	-2.0%	+3.0%	-1.0%	-3.3%	-0.1%	-0.7%
Jan 3	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$7.61	$8.28	+8.8%	+2.2%	+1.8%	+1.2%	+4.6%	-10.4%
Oct 13	UBS	Maintains	Buy → Buy	—	$7.01	$7.14	+1.9%	+12.1%	+10.8%	+15.7%	+18.3%	+8.1%
Aug 22	Credit Suisse	Maintains	Neutral → Neutral	—	$9.00	$9.00	+0.0%	-1.6%	+0.1%	+3.3%	-0.9%	-4.3%
Aug 15	Jefferies	Maintains	Buy → Buy	—	$10.03	$10.57	+5.4%	-0.9%	-4.0%	-10.1%	-9.2%	-10.3%
May 12	Piper Sandler	Maintains	Overweight → Overweight	—	$7.91	$7.76	-1.9%	-2.3%	+3.5%	-3.5%	+8.6%	+3.3%
Apr 28	Credit Suisse	Maintains	Neutral → Neutral	—	$11.66	$11.74	+0.7%	-4.5%	-6.5%	+2.5%	+2.9%	+5.0%
Feb 10	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$15.09	$14.23	-5.7%	-7.6%	-13.5%	-14.4%	-4.0%	-3.9%
Oct 14	SVB Leerink	Maintains	Market Perform → Perform	—	$22.06	$22.11	+0.2%	+5.6%	-3.9%	-1.1%	+2.4%	+7.9%
Jul 19	Piper Sandler	Maintains	Overweight → Overweight	—	$19.29	$19.80	+2.6%	+2.7%	+11.5%	+12.5%	+14.9%	+21.2%
Jul 19	JP Morgan	Maintains	Overweight → Overweight	—	$19.29	$19.80	+2.6%	+2.7%	+11.5%	+12.5%	+14.9%	+21.2%
Jul 19	Guggenheim	Maintains	Buy → Buy	—	$19.29	$19.80	+2.6%	+2.7%	+11.5%	+12.5%	+14.9%	+21.2%

Recent Filings

8-K

Unknown — 8-K Filing

Monte Rosa's three MGD programs entering Phase 2 trials represent validation of its platform technology and substantial clinical milestone achievement, potentially de-risking the pipeline and attracting investor confidence for biotech investors seeking exposure to early-stage therapeutic validation.

Mar 17

8-K

Monte Rosa Therapeutics, Inc. -- 8-K Filing

I cannot provide a meaningful investor analysis based on this summary, as it only contains boilerplate language about an accountant's credentials with no material business information disclosed.

Feb 10

Data updated apr 25, 2026 11:43am · Source: massive.com